ReviewCancer management and research2025
The Intricate Web of MicroRNAs in Modulating EGFR-TKI Resistance in Non-Small Cell Lung Cancer: A Comprehensive Review.
Review in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Circular RNAs in NSCLC: Their Role in Tumorigenesis, Tumor Microenvironment Reshaping, and Response to Therapies.Cancers · 2026Review
- Integrated Bioinformatic and Experimental Analysis of PTEN and DNMT1 Regulation in NSCLC.Biomedicines · 2026Article
- A multi-omics approach to identify the impact of miR-411ed on NSCLC TKI resistance.bioRxiv : the preprint server for biology · 2026Article
- The tumor microenvironment: adding pieces to the puzzle.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) harboring activating mutations in the Epidermal Growth Factor Receptor (EGFR) has been effectively treated with EGFR tyrosine kinase inhibitors (TKIs). However, the clinical efficacy of these targeted therapies is invariably limited by the development of acquired resistance. While secondary mutations like T790M and bypass pathway activation are well-documented mechanisms, there is a growing appreciation for the profound role of epigenetic regulators, particularly microRNAs (miRNAs), in orchestrating the resistant phenotype. This review provides a comprehensive and detailed analysis of the multifaceted roles of miRNAs in the emergence and maintenance of EGFR-TKI resistance in NSCLC, including their regulation of alternative receptor tyrosine kinase signaling pathways, driving phenotypic plasticity, specifically the epithelial-mesenchymal transition (EMT) and the acquisition of cancer stem cell (CSC) characteristics, as well as dysregulating core cellular processes, such as apoptosis. We further examine the complex interplay within competing endogenous RNA (ceRNA) networks, where long non-coding RNAs and circular RNAs sequester miRNAs, thereby modulating the expression of resistance-associated genes. Finally, the potential of specific miRNAs as circulating biomarkers for monitoring treatment response and as therapeutic targets to overcome resistance is discussed. This review underscores the central role of miRNA-mediated gene regulation as a critical layer of complexity in EGFR-TKI resistance, highlighting a sophisticated network that governs the fate of cancer cells under therapeutic pressure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.